earningsconfidence high
Halozyme Q1 revenue up 42% to $377M; new $1B buyback program
HALOZYME THERAPEUTICS, INC.
2026-Q1 EPS
reported $1.22
vs consensus $1.56
▼ miss
(-21.8%)
- Total revenue $376.7M (+42% YoY); royalty revenue $240.7M (+43% YoY).
- GAAP diluted EPS $1.22 (vs $0.93); Non-GAAP diluted EPS $1.60 (vs $1.11).
- New $1B share repurchase program through 2028; at least $400M expected in 2026.
- Reiterated 2026 guidance: revenue $1.71B-$1.81B, Non-GAAP EPS $7.75-$8.25.
- Collaborations: GSK (multiple oncology ENHANZE targets), argenx VYVGART Hytrulo FDA-approved for all gMG serotypes.
item 2.02item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.